Cytovia, Cellectis add CAR-T targets to preexisting cell therapy pact; BridgeBio, Helsinn unveil first program in R&D tie-up
NK cell biotech Cytovia and gene editing firm Cellectis are expanding upon their previous team-up.
The two biotechs announced yesterday they …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
